B · Normal
[Kanghong Pharmaceutical: Subsidiary was approved for clinical trial of KHN923 injection] On November 18, Kanghong Pharmaceutical (002773.SZ) announced that the company's subsidiary Kanghong Biology received the "Drug Clinical Trial Approval Notice" issued by the State Food and Drug Administration, agreeing to conduct clinical trials of KHN923 injection. The drug is a bispecific antibody targeting Aβ/TfR1. It is indicated for Alzheimer’s disease and is registered as a Class 1 therapeutic biological product. The company reminds that there are uncertainties in drug research and development and review results, and investors need to make cautious decisions.
A-share announcement express 🕐 2026-11-18 19:33

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet